Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Open innovation in neuroscience research and drug discovery

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The pressures on the pharmaceutical industry have incentivised a number of new collaborative models of research and development which can be categorised as open innovation. Examples of the different types of models employed are discussed and some, but not all, of these have been used to promote research and drug discovery for central nervous system disorders. Some are completely open access, while others have some intellectual property restrictions. Going forward, more ways of promoting open innovation and the sharing of best practice, especially in the neurosciences, will stimulate research and hopefully accelerate new medicines development.

          Related collections

          Most cited references 25

          • Record: found
          • Abstract: not found
          • Article: not found

          Too many roads not taken.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials.

            Response to antipsychotics in schizophrenia is highly variable, and determinants are not well understood or used to design clinical trials.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Is open innovation the way forward for big pharma?

                Bookmark

                Author and article information

                Journal
                Brain Neurosci Adv
                Brain Neurosci Adv
                BNA
                spbna
                Brain and Neuroscience Advances
                SAGE Publications (Sage UK: London, England )
                2398-2128
                13 September 2018
                Jan-Dec 2018
                : 2
                Affiliations
                [1 ]Benevolent AI, London, UK
                [2 ]Structural Genomics Consortium, Oxford, UK
                [3 ]Action Against Age-related Macular Degeneration, London, UK
                Author notes
                Ann J. Hunter, Benevolent AI, 40 Churchway, NW1 1LW, London, UK. Email: jackie.hunter@ 123456benevolent.ai
                Article
                10.1177_2398212818799270
                10.1177/2398212818799270
                7058200
                © The Author(s) 2018

                This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ( http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ( https://us.sagepub.com/en-us/nam/open-access-at-sage).

                Categories
                Review Article
                Custom metadata
                January-December 2018

                Comments

                Comment on this article